1. Home
  2. ICD-10-CM Codes
  3. R00–R99
  4. R97
  5. R97
  6. 2024 ICD-10-CM Code R97
Version 2024
Non-Billable Code
No Valid Principal Dx

2024 ICD-10-CM Diagnosis Code R97

Abnormal tumor markers

ICD-10-CM Code:
R97
ICD-10 Code for:
Abnormal tumor markers
Is Billable?
Not Valid for Submission
Code Navigator:

Code Classification

  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
    (R00–R99)
    • Abnormal tumor markers
      (R97)
      • Abnormal tumor markers
        (R97)

R97 is a non-specific and non-billable diagnosis code code, consider using a code with a higher level of specificity for a diagnosis of abnormal tumor markers. The code is not specific and is NOT valid for the year 2024 for the submission of HIPAA-covered transactions. Category or Header define the heading of a category of codes that may be further subdivided by the use of 4th, 5th, 6th or 7th characters.

According to ICD-10-CM guidelines this code should not to be used as a principal diagnosis code when a related definitive diagnosis has been established.

Specific Coding Applicable to Abnormal tumor markers

Non-specific codes like R97 require more digits to indicate the appropriate level of specificity. Consider using any of the following ICD-10-CM codes with a higher level of specificity when coding for abnormal tumor markers:

  • Use R97.0 for Elevated carcinoembryonic antigen [CEA] - BILLABLE CODE

  • Use R97.1 for Elevated cancer antigen 125 [CA 125] - BILLABLE CODE

  • R97.2 for Elevated prostate specific antigen [PSA] - NON-BILLABLE CODE

  • Use R97.20 for Elevated prostate specific antigen [PSA] - BILLABLE CODE

  • Use R97.21 for Rising PSA following treatment for malignant neoplasm of prostate - BILLABLE CODE

  • Use R97.8 for Other abnormal tumor markers - BILLABLE CODE

Tabular List of Diseases and Injuries

The following annotation back-references are applicable to this diagnosis code. The Tabular List of Diseases and Injuries is a list of ICD-10-CM codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more.


Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Elevated tumor associated antigens TAA
  • Elevated tumor specific antigens TSA

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.